IBDEI063 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2605,1,1,0)
 ;;=1^V15.81
 ;;^UTILITY(U,$J,358.3,2605,1,2,0)
 ;;=2^HX OF PAST NONCOMPLIANCE
 ;;^UTILITY(U,$J,358.3,2605,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,2606,0)
 ;;=401.9^^22^206^9
 ;;^UTILITY(U,$J,358.3,2606,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2606,1,1,0)
 ;;=1^401.9
 ;;^UTILITY(U,$J,358.3,2606,1,2,0)
 ;;=2^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,2606,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,2607,0)
 ;;=V58.61^^22^206^10
 ;;^UTILITY(U,$J,358.3,2607,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2607,1,1,0)
 ;;=1^V58.61
 ;;^UTILITY(U,$J,358.3,2607,1,2,0)
 ;;=2^L/T (CURRENT) USE - ANTICOAG
 ;;^UTILITY(U,$J,358.3,2607,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,2608,0)
 ;;=V65.19^^22^206^14
 ;;^UTILITY(U,$J,358.3,2608,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2608,1,1,0)
 ;;=1^V65.19
 ;;^UTILITY(U,$J,358.3,2608,1,2,0)
 ;;=2^PERSON CONSULT FOR ANOTH
 ;;^UTILITY(U,$J,358.3,2608,2)
 ;;=^329985
 ;;^UTILITY(U,$J,358.3,2609,0)
 ;;=272.4^^22^206^8
 ;;^UTILITY(U,$J,358.3,2609,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2609,1,1,0)
 ;;=1^272.4
 ;;^UTILITY(U,$J,358.3,2609,1,2,0)
 ;;=2^HYPERLIPIDEMIA NOS
 ;;^UTILITY(U,$J,358.3,2609,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,2610,0)
 ;;=285.29^^22^206^1
 ;;^UTILITY(U,$J,358.3,2610,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2610,1,1,0)
 ;;=1^285.29
 ;;^UTILITY(U,$J,358.3,2610,1,2,0)
 ;;=2^ANEMIA IN CHRONIC ILLNESS
 ;;^UTILITY(U,$J,358.3,2610,2)
 ;;=^334228
 ;;^UTILITY(U,$J,358.3,2611,0)
 ;;=585.6^^22^206^4
 ;;^UTILITY(U,$J,358.3,2611,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2611,1,1,0)
 ;;=1^585.6
 ;;^UTILITY(U,$J,358.3,2611,1,2,0)
 ;;=2^ESRD
 ;;^UTILITY(U,$J,358.3,2611,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,2612,0)
 ;;=V58.69^^22^206^11
 ;;^UTILITY(U,$J,358.3,2612,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2612,1,1,0)
 ;;=1^V58.69
 ;;^UTILITY(U,$J,358.3,2612,1,2,0)
 ;;=2^L/T CURRENT USE OF OTHER MEDS
 ;;^UTILITY(U,$J,358.3,2612,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,2613,0)
 ;;=V58.83^^22^206^15
 ;;^UTILITY(U,$J,358.3,2613,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2613,1,1,0)
 ;;=1^V58.83
 ;;^UTILITY(U,$J,358.3,2613,1,2,0)
 ;;=2^THERAPEUTIC DRUG MONITORING
 ;;^UTILITY(U,$J,358.3,2613,2)
 ;;=^322076
 ;;^UTILITY(U,$J,358.3,2614,0)
 ;;=V58.61^^22^207^14
 ;;^UTILITY(U,$J,358.3,2614,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2614,1,1,0)
 ;;=1^V58.61
 ;;^UTILITY(U,$J,358.3,2614,1,2,0)
 ;;=2^L/T (CURRENT) USE - ANTICOAG
 ;;^UTILITY(U,$J,358.3,2614,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,2615,0)
 ;;=427.31^^22^207^1
 ;;^UTILITY(U,$J,358.3,2615,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2615,1,1,0)
 ;;=1^427.31
 ;;^UTILITY(U,$J,358.3,2615,1,2,0)
 ;;=2^ATRIAL FIBRILLATION
 ;;^UTILITY(U,$J,358.3,2615,2)
 ;;=^11378
 ;;^UTILITY(U,$J,358.3,2616,0)
 ;;=427.32^^22^207^2
 ;;^UTILITY(U,$J,358.3,2616,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2616,1,1,0)
 ;;=1^427.32
 ;;^UTILITY(U,$J,358.3,2616,1,2,0)
 ;;=2^ATRIAL FLUTTER
 ;;^UTILITY(U,$J,358.3,2616,2)
 ;;=^11387
 ;;^UTILITY(U,$J,358.3,2617,0)
 ;;=414.00^^22^207^3
 ;;^UTILITY(U,$J,358.3,2617,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2617,1,1,0)
 ;;=1^414.00
 ;;^UTILITY(U,$J,358.3,2617,1,2,0)
 ;;=2^CAD
 ;;^UTILITY(U,$J,358.3,2617,2)
 ;;=^28512
 ;;^UTILITY(U,$J,358.3,2618,0)
 ;;=425.4^^22^207^4
 ;;^UTILITY(U,$J,358.3,2618,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2618,1,1,0)
 ;;=1^425.4
 ;;^UTILITY(U,$J,358.3,2618,1,2,0)
 ;;=2^CARDIOMYOPATHY
 ;;^UTILITY(U,$J,358.3,2618,2)
 ;;=^87808
 ;;^UTILITY(U,$J,358.3,2619,0)
 ;;=V65.49^^22^207^5
 ;;^UTILITY(U,$J,358.3,2619,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,2619,1,1,0)
 ;;=1^V65.49
